These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
54. Recent progress in the understanding and treatment of transthyretin amyloidosis. Sekijima Y J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898 [TBL] [Abstract][Full Text] [Related]
55. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. Maia LF; Magalhães R; Freitas J; Taipa R; Pires MM; Osório H; Dias D; Pessegueiro H; Correia M; Coelho T J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):159-67. PubMed ID: 25091367 [TBL] [Abstract][Full Text] [Related]
56. Clinical picture and outcome of transthyretin-related familial amyloid polyneuropathy (FAP) in Japanese patients. Ikeda S Clin Chem Lab Med; 2002 Dec; 40(12):1257-61. PubMed ID: 12553427 [TBL] [Abstract][Full Text] [Related]
57. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Herlenius G; Wilczek HE; Larsson M; Ericzon BG; Transplantation; 2004 Jan; 77(1):64-71. PubMed ID: 14724437 [TBL] [Abstract][Full Text] [Related]
58. Kidney and anemia in familial amyloidosis type I. Beirão I; Lobato L; Costa PM; Fonseca I; Mendes P; Silva M; Bravo F; Cabrita A; Porto G Kidney Int; 2004 Nov; 66(5):2004-9. PubMed ID: 15496172 [TBL] [Abstract][Full Text] [Related]
59. Wild-type transthyretin cardiac amyloidosis diagnosed in a patient in his 50s. Tanabe J; Ouchi T; Watanabe N; Tanabe K BMJ Case Rep; 2020 Jun; 13(6):. PubMed ID: 32606107 [No Abstract] [Full Text] [Related]
60. Survival After Transplantation in Patients With Mutations Other Than Val30Met: Extracts From the FAP World Transplant Registry. Suhr OB; Larsson M; Ericzon BG; Wilczek HE; Transplantation; 2016 Feb; 100(2):373-81. PubMed ID: 26656838 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]